Chloramphenicol succinate

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Chloramphenicol succinate
Accession Number
DB07565
Type
Small Molecule
Groups
Approved
Description
Not Available
Structure
Thumb
Synonyms
  • Chloramphenicol hemisuccinate
Product Ingredients
IngredientUNIICASInChI Key
Chloramphenicol sodium succinate872109HX6B982-57-0RPLOPBHEZLFENN-HTMVYDOJSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chloromycetin Sodium SuccinateInjection100 mg/1mLIntravenousMonarch Pharmaceuticals, Inc.1959-02-202007-10-05Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chloramphenicol Sodium SuccinateInjection, powder, lyophilized, for solution1 g/10mLIntravenousGeneral Injectables & Vaccines2010-09-012017-01-18Us
Chloramphenicol Sodium SuccinateInjection, powder, lyophilized, for solution1 g/10mLIntravenousFresenius Kabi2001-01-12Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
ZCX619U9A1
CAS number
3544-94-3
Weight
Average: 423.202
Monoisotopic: 422.028370912
Chemical Formula
C15H16Cl2N2O8
InChI Key
LIRCDOVJWUGTMW-ZWNOBZJWSA-N
InChI
InChI=1S/C15H16Cl2N2O8/c16-14(17)15(24)18-10(7-27-12(22)6-5-11(20)21)13(23)8-1-3-9(4-2-8)19(25)26/h1-4,10,13-14,23H,5-7H2,(H,18,24)(H,20,21)/t10-,13-/m1/s1
IUPAC Name
4-[(2R,3R)-2-(2,2-dichloroacetamido)-3-hydroxy-3-(4-nitrophenyl)propoxy]-4-oxobutanoic acid
SMILES
O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UDr hemagglutinin structural subunitNot AvailableEscherichia coli
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with 4-hydroxycoumarin.
AcenocoumarolThe risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Acenocoumarol.
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Chloramphenicol succinate.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Chloramphenicol succinate.
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Chloramphenicol succinate.
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Chloramphenicol succinate.
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Chloramphenicol succinate.
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Chloramphenicol succinate.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C11727
PubChem Compound
656580
PubChem Substance
99444036
ChemSpider
570947
ChEMBL
CHEMBL1201281
HET
CL8
Wikipedia
Chloramphenicol
PDB Entries
2jkn / 2w5p

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous1 g/10mL
InjectionIntravenous100 mg/1mL
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.112 mg/mLALOGPS
logP1.34ALOGPS
logP1.14ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)3.65ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area156.07 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity92.24 m3·mol-1ChemAxon
Polarizability37.74 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6818
Blood Brain Barrier+0.9097
Caco-2 permeable-0.5067
P-glycoprotein substrateNon-substrate0.6633
P-glycoprotein inhibitor INon-inhibitor0.7924
P-glycoprotein inhibitor IINon-inhibitor0.8358
Renal organic cation transporterNon-inhibitor0.923
CYP450 2C9 substrateNon-substrate0.8336
CYP450 2D6 substrateNon-substrate0.8552
CYP450 3A4 substrateNon-substrate0.5375
CYP450 1A2 substrateNon-inhibitor0.6683
CYP450 2C9 inhibitorInhibitor0.5155
CYP450 2D6 inhibitorNon-inhibitor0.8638
CYP450 2C19 inhibitorInhibitor0.797
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6768
Ames testNon AMES toxic0.9159
CarcinogenicityNon-carcinogens0.7575
BiodegradationNot ready biodegradable0.6038
Rat acute toxicity1.9742 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9022
hERG inhibition (predictor II)Non-inhibitor0.781
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as nitrobenzenes. These are compounds containing a nitrobenzene moiety, which consists of a benzene ring with a carbon bearing a nitro group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Nitrobenzenes
Direct Parent
Nitrobenzenes
Alternative Parents
Nitroaromatic compounds / Fatty acid esters / Dicarboxylic acids and derivatives / Secondary carboxylic acid amides / Secondary alcohols / Carboxylic acid esters / Propargyl-type 1,3-dipolar organic compounds / Carboxylic acids / Organic oxoazanium compounds / Organic oxides
show 8 more
Substituents
Nitrobenzene / Nitroaromatic compound / Fatty acid ester / Dicarboxylic acid or derivatives / Fatty acyl / Carboxamide group / Carboxylic acid ester / C-nitro compound / Organic nitro compound / Secondary alcohol
show 23 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Escherichia coli
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Hemagglutinins of uropathogenic E.coli mediate adherence to the upper urinary tract. These adhesins bind to the Dr blood group antigen and also agglutinate human erythrocytes in the presence of D-m...
Gene Name
draA
Uniprot ID
P24093
Uniprot Name
Dr hemagglutinin structural subunit
Molecular Weight
17058.095 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 15, 2010 15:23 / Updated on September 02, 2019 21:47